VIATRIS INC. Fair Value, Assets and Liabilities Measured on Recurring Basis, Gain (Loss) Included in Earnings
VIATRIS INC. (VTRS) reported Fair Value, Assets and Liabilities Measured on Recurring Basis, Gain (Loss) Included in Earnings of $20.40 million for the 12-month period ending 2019-12-31, per its 10-K filed 2021-03-01.
Discontinued › Income Statement › Other Income
us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings · last filed 2021-03-01
- VIATRIS INC. fair value, assets and liabilities measured on recurring basis, gain (loss) included in earnings for fiscal 2019 was $20.40M.
| Period end | Fair Value, Assets and Liabilities Measured on Recurring Basis, Gain (Loss) Included in Earnings 12 month |
|---|---|
| 2019-12-31 | $20.40M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |